Preparation of Grant Application for a Clinical Phase Ib Trial with NeuroRestore ACD856
| Reference number | |
| Coordinator | AlzeCure Pharma AB |
| Funding from Vinnova | SEK 300 000 |
| Project duration | October 2023 - October 2024 |
| Status | Completed |
| Venture | Preparation projects for international application within health |
| Call | Preparation project for international proposal in health and food 2023 |
Important results from the project
The goal of this preparatory project, which was to compile a competitive grant application to the European Innovation Council (EIC) in order to conduct a clinical study with the innovative drug candidate NeuroRestore ACD856, was completed according to plan. The grant application was submitted in October 2024.
Expected long term effects
If the project is awarded a grant from the EIC, the planned clinical study with NeuroRestore ACD856 will be carried out, which may lead to a new drug candidate becoming available for patients with Alzheimer´s disease in the future.
Approach and implementation
The team first submitted a so-called “step 1” proposal to the EIC which was written to assess whether the project fitted the EIC programme objectives. After the project was approved in stage 1, work began on the significantly more comprehensive proposal for stage 2. The application material was created and carefully worked through within the project team and in collaboration with several external experts.